| Name | Title | Contact Details |
|---|
Ignyta, located in San Diego, California, is a biotechnology company developing precision medicine with integrated Rx/Dx solutions for cancer patients. Its goal is to discover and develop revolutionary new drugs that target activated genes in cancer cells for the customized treatment of cancer patients. The company's present focus is on the development of RXDX-101, its proprietary oral tyrosine kinase inhibitor that targets solid tumor indications, and advancing its novel Spark discovery programs that leverage its proprietary cancer genomic and epigenomic knowledge bases
Home Advantage is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SkinMedica, Inc. is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Nano Mark, Llc is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oncobiologics is a U.S. based biotechnology firm focused on the development, manufacture and commercialization of biosimilar versions of leading global biopharmaceuticals. The firm was founded in 2011 by a team of highly accomplished scientists and engineers from leading pharma and biotech organizations. Since its establishment, Oncobiologics has leveraged its scientific strengths and technical infrastructure to rapidly develop a portfolio of therapeutically important and commercially-attractive complex biosimilars (monoclonal antibodies), with its first asset entering Phase I clinical trials in Europe in June 2014 and Phase III in Q1/2015.